| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.2 | 3.5 |
| Profit before tax | -2.2 | -4.3 |
| Net income | -2.2 | -4.3 |
| EPS (diluted, $ a share) | $-0.15 | $-0.32 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -64.6% |
|---|---|
| Operating margin | -242.6% |
10-Q filed with the SEC, NASDAQ: ATRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Atara Biotherapeutics, Inc.: key numbers
- Share price
- $6.50Close, Nov 17
- Market cap
- $66.2M
- Shares outstanding
- 10.19MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Atara Biotherapeutics, Inc.
All →Atara Biotherapeutics Financial Results
Atara Biotherapeutics reported Q3 2026 financial results, highlighting a significant 83% year-over-year reduction in operating expenses and a net loss of $2.2 million. The company is focused on the FDA's March 31, 2027, PDUFA date for tab-cel, which if approved would trigger a $31 million milestone payment from Pierre Fabre Laboratories.
“The resubmission of the tab-cel BLA was an important milestone this quarter, and we remain focused on supporting Pierre Fabre Pharmaceuticals (PFP) toward a successful outcome. We continue to believe in tab-cel’s significant commercial potential in the U.S. In parallel, we are taking steps to control expenses with the goal of protecting and maximizing shareholder value while enhancing our strategic flexibility.”
Cokey Nguyen, President and Chief Executive Officer